baber/WOPTO huggingface dataset:
Patent NZ-587836-A (NZ)
Title: Manual apparatus for filling cigarette tubes with tobacco
Inventor: DEMMER UDO
IPC: B65D5/00
Filed: 2009-03-17
Abstract: Apparatus for filling cigarette tubes with tobacco, comprises a base10, a magazine chamber 2, a lid 20, a pusher 24, a filling chamber 24, a stamp 30, a slider 50, a press-down lever 6 and a coupling mechanism 79. The magazine chamber 2 is adapted to receive a supply of tobacco T, and has a base wall 12, two side walls 14 opposite to each other, a first end wall 16 and a second end wall 18 opposite to the first end wall 16. The lid 20 is adapted to close the top side of the magazine chamber 2. The pusher 24 is adapted to move the tobacco T inside the magazine chamber 2 towards its first end wall 16. The filling chamber 4 which is in proximity to the first end wall 16 of the magazine chamber 2, defines a longitudinal direction L that is transverse to the moving direction A of the pusher 24 and is adapted to receive the tobacco to be filled into the cigarette tube. The stamp 30 is movable in a direction that is transverse to the moving direction A of the pusher 24 and transverse to the longitudinal direction L of the filling chamber 4 and is adapted to shape the tobacco of the filling chamber 4. The slider 50 is arranged in the filling chamber 4, is movable in the longitudinal direction L thereof towards an opening in an end wall, and is adapted to transfer the tobacco of the filling chamber 4 from the filling chamber 4 via the opening into a cigarette tube supported in front of the opening. The press-down lever 6 is operatively connected to the stamp 30, and is adapted to move the stamp 30. The coupling mechanism 79 is operatively connected to the press-down lever 6 and is adapted to move the slider 50 after the tobacco has been transferred to the filling chamber and has been shaped by the stamp 30.
Patent NZ-588323-A (NZ)
Title: Markers for the detection of gastric cancer
Inventor: GUILFORD PARRY JOHN
IPC: C12Q1/68
Filed: 2004-07-16
Abstract: Provided is a method of detecting gastric cancer, comprising: detecting over-expression of the GTM family member serine or cysteine proteinase inhibitor clade B (SERPINB5) in a biological sample. The method can be improved by further including other specified markers. The overexpression can be measured by mRNA, cDNA, or protein level by antibody based assay.
Patent NZ-592286-A (NZ)
Title: Thyroid receptor ligands
Inventor: RAVAL SAURIN
IPC: C07D211/96
Filed: 2009-10-22
Abstract: Disclosed are thyroid receptor ligand compounds of formula (I), wherein the substituents are as described within the specification. Examples of compounds of formula (I) include: 2-(((3,5-dichloro-4-(4-hydroxy-3-isopropyl phenoxy)benzylidene)amino)oxy) acetic acid; and 2-(((3,5-dibromo-4-((6-hydroxy-[1,1'-biphenyl]-3-yl)oxy)benzylidene)amino)oxy)butanoic acid. Further disclosed is a pharmaceutical composition comprising a compound of formula (I), and the use of a compound of formula (I) in the manufacture of a medicament for preventing or treating diseases caused by dyslipidemia obesity. Also disclosed are compounds as intermediates for the preparation of a compound of formula (I).
Patent NZ-593390-A (NZ)
Title: Process for the manufacturing of vinyl acetate
Inventor: RINNE BERND
IPC: C07C67/58
Filed: 2009-11-28
Abstract: A process for the separation of vinyl acetate (ethenyl ethanoate) from a gas mixture formed by the reaction of ethylene with acetic acid and oxygen in the gas phase over catalysts comprising palladium or palladium compounds comprising a) introducing said gas mixture leaving the vinyl acetate reactor into a predewatering column, b) cooling the gas mixture leaving the top of predewatering column below 85 degrees, preferably to a temperature below 80 degrees and most preferably to a temperature between 55 degrees and 75 degrees in a countercurrent heat exchanger, c) further cooling the gas mixture or the gas and liquid mixture leaving the heat exchanger in step b) to from -20 to 50 degrees with the condensate obtained separating into an aqueous phase and an organic phase, d) taking off the water phase formed in step c), e) recirculating all or part of the organic phase formed in step c) as reflux to the top of the dewatering column utilized in step a) and taking off part of the organic phase which is not used as reflux, f) scrubbing the gas comprising vinyl acetate which is not condensed in step b) in a gas scrubbing column by means of an aqueous acetic acid solution, g) isolating the vinyl acetate, h) heating the recycle gas leaving the scrubbing column, optionally together with fresh ethylene and/or recycle gas coming from a carbon dioxide removal system and/or flash gas in the countercurrent heat exchanger, and thereby reducing the temperature of the gas mixture leaving the top of the dewatering column, and i) introducing the recycle gas optionally together with fresh ethylene and/or recycle gas coming from a CO2 removal system and/or flash gas preheated in step h) into the vinyl acetate reactor.
Patent NZ-599556-A (NZ)
Title: Combination therapy with a compound acting as a platelet adp receptor inhibitor
Inventor: CONLEY PAMELA B
IPC: A61K31/235
Filed: 2008-05-02
Abstract: Abstract - 599556 Disclosed herein is the use of a first therapeutic agent of [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2Hquinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a condition in a mammal selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary arteryl bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prosthesis, wherein the medicament is for administration in combination with a second therapeutic agent which is selected from the group consisting of a specific inhibitor of thrombin, a P-selectin inhibitor, a specific inhibitor of factor XIIa, low molecular weight heparin, acenocoumarol, clorindione, dicumarol, diphenadione, ethyl biscoumacetate, phenprocoumon, phenindione, tioclomarol, an anti-tissue factor antibody, fragmin, NAP-5, rNAPc2, a P2Y12 receptor antagonist, a tissue factor pathway inhibitor, ramatroban, terbogrel, (3-{ 6-[(4-chlorophenylsulfonyl)amino]-2-methyl-5,6,7,8-tetrahydronaphth-1-yl} propionic acid, ethyl (1R,3aR,4aR,6R, 8aR, 9S, 9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-C] furan-6-ylcarbamate, 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ibuprofen, a beta blocker, a calcium channel blocker and PSGL-1.
Patent NZ-600154-A (NZ)
Title: Method and apparatus for washing metallurgical waste powder in the form of granules
Inventor: REILLY LEONARD FRANCIS
IPC: B03B9/04
Filed: 2010-11-22
Abstract: 600154 Disclosed is a process for processing finely divided material produced during a metallurgical process. The finely divided material is dust generated during steel production when using an electric arc furnace. The process comprises continuous washing. A first portion of granules are washed continuously by movement of the granules through a wash solution by an axial screw (3) driven by a motor (4). The suspended solids content of the solution increases as a result of washing the granules. The washing of the granules takes place in a vessel (2) comprising a second portion of granules. The second portion of granules which are completely submerged by the wash solution are provided to reduce the suspended solids content of the solution. The first and second portions of granules are continuously removed from the vessel (2) and replenished with fresh portions of granules for processing.
Patent NZ-600430-A (NZ)
Title: Spiro-oxindole mdm2 antagonists
Inventor: WANG SHAOMENG
IPC: A61K31/407
Filed: 2010-11-10
Abstract: Provided herein are compounds of formula I, wherein the variables are defined in the specification, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. In one embodiment the compound is 6-chloro-4’-(3-chlorophenyl)-N-(3,4-dihydroxy-3-methylbutyl)-5-fluoro-2’-neopentyl-2-ocospiro[indoline-3,3’-pyrrolidine]-5’-carboxamide.
Patent NZ-601801-A (NZ)
Title: Substrate geometry for a filtration membrane
Inventor: LESCOCHE PHILIPPE
IPC: B01D63/06
Filed: 2011-03-04
Abstract: 601801 A filtration element (I) for filtering a fluid medium is disclosed. The element has a cylindrical, rigid, porous substrate having a longitudinal central axis (A) and including a plurality of channels through which the fluid medium to be filtered can flow, in order for a filtrate to be obtained at the periphery of the substrate. The channels are provided in the substrate parallel to the central axis (A) thereof and defining at least three concentric filtration areas separated from one another by a continuous porous area. The invention is characterised in that the mean thickness (eZ1) of the porous area (Z1) closest to the central axis (A) is less than the mean thickness (eZ2) of the next porous area (Z2). This relationship holds true out to the periphery (11) of the substrate (1) where each successive porous area’s mean thickness is the same or greater than the last. The Applicant has found that the substrate is subjected to strong stresses, having regard to the pressures applied during filtering operations, and could have points of weakness at some points of their structure. In particular, the Applicant has evaluated the stress fields existing within the substrates of the prior art and has found that maximum stress increases in the direction moving away from the centre towards the outside of the support. Having each successive porous area’s mean thickness as the same or greater than the last helps mediate this stress on the structure.
Patent NZ-609228-A (NZ)
Title: Sleeve seal for gate valves
Inventor: NGUYEN VIET
IPC: F16K3/10
Filed: 2011-09-16
Abstract: Disclosed is a gate valve sleeve (1) with reinforcing. The gate valve sleeve comprises a cylindrical sleeve member (16) having a nose portion (24) disposed at one end, and a reinforcing member (32) substantially encased within the cylindrical sleeve member. The reinforcing member (32) comprises first and second ring members connected by a plurality of spacer members, wherein one of the ring members is positioned adjacent to the nose portion. The first ring member comprises a broad side surface which faces towards the nose portion.
Patent NZ-617104-A (NZ)
Title: Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
Inventor: BHAGWAT SACHIN SUBHASH
IPC: A61P31/04
Filed: 2011-10-04
Abstract: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.
Patent NZ-623726-A (NZ)
Title: Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof
Inventor: KWON SE CHANG
IPC: A61P7/04
Filed: 2012-10-05
Abstract: Disclosed is a derivative of FacⅦ or its active form FacⅦa, comprising the amino acid sequence of SEQ ID NO. 4 from FacⅦ and a peptide linker linked at the C-terminus thereof, wherein the C-terminal amino acid residue of the peptide linker is a cysteine, wherein the sequence is defined in the complete specification. Also disclosed is the use of said compound for the preparation of a medicament for preventing or treating haemophilia or for promoting blood coagulation.
Patent NZ-624189-A (NZ)
Title: Pharmaceutical compounds for use in the therapy of clostridium difficile infection
Inventor: CASTAGNER BASTIEN
IPC: C07F9/117
Filed: 2012-09-28
Abstract: Provided are poly-phosphate, polysulfate or mixed polyphosphate/sulfate derivatives of six-membered cyclic polyol compounds, of general formulae (1) and (15), wherein the variables are as defined in the specification. The compounds are analogues of inositol hexakisphosphate (IP6)/phytic acid. An example of the compounds is myo-inositol-pentakisphosphate-2-PEG(400). The compounds are enteric activators of Clostridium difficile toxin. The compounds are useful in the treatment of Clostridium difficile infection.
Patent NZ-629473-A (NZ)
Title: Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
Inventor: DEMOPULOS GREGORY A
IPC: A61K39/00
Filed: 2013-06-18
Abstract: Disclosed is the use of a MASP-3 inhibitory agent in the manufacture of a medicament for treating a subject suffering from, or at risk for developing, a disease or disorder selected from the group consisting of age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotising crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet’s disease, wherein said MASP-3 inhibitory agent is a MASP-3 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:8 and inhibits factor D maturation.
Patent NZ-714517-A (NZ)
Title: Delayed release cysteamine bead formulation
Inventor: POWELL KATHLENE
IPC: A61K31/145
Filed: 2014-06-17
Abstract: The present invention provides a delayed release cysteamine bead formulation. In particular, the present invention provides a pharmaceutical dosage form, comprising delayed release cysteamine beads, the beads comprising: (i) a core particle comprising cysteamine or a pharmaceutically acceptable salt thereof and a binder, and (ii) an enteric membrane surrounding the core particle, wherein the beads have a distribution of particle sizes in a range of about 0.7 mm to about 2.8 mm; wherein the enteric membrane begins to dissolve within a pH range of about 4.5 to about 6.5; wherein the enteric membrane is present in an amount in a range of about 25% to about 35% by weight, based on the weight of the core particles; and wherein the pharmaceutical dosage form, upon administration in a capsule to fasted healthy normal subjects at 600 mg free cysteamine base, provides: (a) a mean Cmax upon oral dosing in a range of 2.3 ± 0.6 mg/L or in a range of 80% to 125% thereof; and (b) a mean AUC (0-inf_D) upon oral dosing in a range of 0.84 ± 0.19 min*mg/L/mg or in a range of 80% to 125% thereof. The enterically-coated cysteamine composition increases delivery of cysteamine to the small intestine resulting in less frequent dosing compared to non-enteric coated cysteamine.
Patent NZ-720901-A (NZ)
Title: Lactobacillus salivarius for the treatment of mastitis
Inventor: MARTIN ROCIO
IPC: C12R1/225
Filed: 2014-12-19
Abstract: The invention relates to a new strain of Lactobacillus salivarius, products containing the new strain, the use thereof in and methods for the treatment and/or prevention of inflammation and/or infection in breast or udder tissue, particularly in a mammary gland of a human female. The inflammation and/or infection is preferably mastitis.
Patent NZ-728027-A (NZ)
Title: Reduction of infections in healthcare settings using photocatalytic compositions
Inventor: AVERETT STEWART
IPC: A01N59/00
Filed: 2015-06-22
Abstract: Methods of reducing the incidence of healthcare-associated infections in various healthcare settings are provided. Methods for preventing or reducing the number of infections in a human or animal population are also provided. Such methods involve the application of a photocatalytic composition comprising TiO2 doped with zinc and Si or SiO2 to a surface. The methods as provided herein reduce the presence of various infectious agents that are commonly acquired or transmitted and are present on both animate and inanimate surfaces, including those infectious agents commonly found in healthcare settings. By reducing the presence of such infectious agents, the incidence of various types of infection or disease is thereby reduced.
Patent NZ-741924-A (NZ)
Title: Methods for 2-color radiography with laser-compton x-ray sources
Inventor: BARTY CHRISTOPHER P J
IPC: A61B6/03
Filed: 2015-05-07
Abstract: High-contrast, subtraction, x-ray images of an object are produced via scanned illumination by a laser-Compton x-ray source. The spectral-angle correlation of the laser-Compton scattering process and a specially designed aperture and/or detector are utilized to produce/record a narrow beam of x-rays whose spectral content consists of an on-axis region of high-energy x-rays surrounded by a region of slightly lower-energy x-rays. The end point energy of the laser-Compton source is set so that the high-energy x-ray region contains photons that are above the k-shell absorption edge (k-edge) of a specific contrast agent or specific material within the object to be imaged while the outer region consists of photons whose energy is below the k-edge of the same contrast agent or specific material. Scanning the illumination and of the object by this beam will simultaneously record and map the above k-edge and below k-edge absorption response of the object. The two energy regions are detected by either dithering the detector relative to said beam regions or dithering an aperture relative to the detector and said beam regions.
Patent NZ-747431-A (NZ)
Title: Fading reduced beverage
Inventor: NAGAO KOJI
IPC: A23L2/60
Filed: 2017-02-03
Abstract: The present invention has an object to provide a beverage wherein fading of a caramel coloring is reduced. The present invention also has an object to provide a method for producing such a beverage and a method for reducing the caramel coloring fading in the beverage. The beverage meeting the following conditions (A) and (B): (A) a ratio of a content of RebD or RebM to a content of RebA is 0.45 or more, and (B) a caramel coloring is contained so that Lab values of the beverage are respectively L: 45 to 55, a: 10 to 20, and b: 25 to 35.
Patent NZ-758505-A (NZ)
Title: Multi-depth plane display system with reduced switching between depth planes
Inventor: HARRISES CHRISTOPHER
IPC: H04N13/122
Filed: 2017-02-10
Abstract: Methods and systems for reductions in switching between depth planes of a multi-depth plane display system are disclosed. The display system may be an augmented reality display system configured to provide virtual content on a plurality of depth planes using different wavefront divergence. The system monitors the fixation points based upon the gaze of each of the user’s eyes, with each fixation point being a three-dimensional location in the user’s field of view. Location information of virtual objects to be presented to the user is obtained, with a depth of each virtual object being associated with accommodation cues. The one or more accommodation cues associated with the virtual object is adjusted based upon the fixation point of the user’s eyes based on an indication of user preference or a determination that a first virtual object is being fixated on less than the second object.
Patent NZ-765654-A (NZ)
Title: Flow Generator Message System
Inventor: DANTANARAYANA MUDITHA PRADEEP
IPC: A61M16/00
Filed: 2006-10-13
Abstract: A processor (118) for use with a CPAP apparatus, the processor configured to determine the type of patient interface (114) used, select a breathable gas supply pressure based on the determined type of patient interface, generate a message based on the patient interface, and send the message to a recipient remote from the flow generator (110).
Patent PT-102077-A (PT)
Title: Active dry yeast QD145 for winemaking purposes
IPC: C12R1/865
Filed: 1997-11-10
Abstract: Active dry yeast QD145 for winemaking purposes. Origin: strain selected from indigenous flora from the Demarcated Region of Dao by the Technical Services of the Regional Vine Growing Commission of Dao - Federation of Vintners of Dao. Scientific name: Saccharomyces cerevisiae cerevisiae.
Patent PT-102159-A (PT)
Title: Utensil for picking up objects from the floor and from places to which access is difficult
IPC: E01H1/12
Filed: 1998-05-26
Abstract: Utensil designed for picking up objects, formed by a plastic handle in the form of a gun 1, in which a plastic trigger 2 is inserted, moved by the utensil's operator. When the trigger is pressed, two strips of steel 4 fixed to it are pushed and work via the inside of the central aluminium tube 3. Contraction of the steel strips causes two suction cups 7 fixed at the other end of the strips to be pushed one against the other, allowing objects to be secured. The suction cups are fixed to the steel strips by a screw and nut 6, which also fix the two, fixed steel strips 4 at their other end to the central aluminium bar and act as springs that return the suction cups to their initial position after pressure on the trigger is lowered. <IMAGE>
Patent PT-102331-A (PT)
Title: Procedure for complete recovery of iron (III) uses (2-ethyl hexyl) methyl amino phosphonic acid from aqueous media of high acidity
Inventor: DELMAS FRANCISCO
IPC: C22B3/20
Filed: 1999-07-09
Abstract: Iron (III) is completely recovered from aqueous media of high acidity using (2-ethyl hexyl) methyl amino phosphonic acid with the application of liquid-liquid extraction technology. The procedure consists of continuous contact in counterflow of the extractant charged with iron coming from a conventional extractor-separator with sulfuric acid in a re-extractor with one, two or more stages. The process occurs in inert atmosphere in the presence of carbon steel filings.
Patent PT-103569-A (PT)
Title: Processo electrónico de avaliação e certificação de sistemas de gestão de informação
Inventor: CRUZ RUI PEDRO FERREIRA
IPC: G06Q90/00
Filed: 2006-09-26
Abstract: A PRESENTE INVENÇÃO DIZ RESPEITO A UM PROCESSO DE AVALIAÇÃO E CERTIFICAÇÃO DE SISTEMA DE GESTÃO DE INFORMAÇÃO APRESENTANDO A SOLUÇÃO QUE PERMITE AVALIAR E QUANTIFICAR O NÍVEL EVOLUTIVO DO SISTEMA DE GESTÃO DE INFORMAÇÃO NUMA ORGANIZAÇÃO, E PERMITE UMA FORMA DE CERTIFICAÇÃO DO SISTEMA. A UTILIZAÇÃO DESTE PROCESSO PERMITE AVALIAR DE UMA FORMA QUANTITATIVA O SISTEMA DE GESTÃO DE INFORMAÇÃO, IDENTIFICAR AS FRAGILIDADES DO SISTEMA E DETERMINAR UM CONJUNTO DE ACÇÕES CORRECTIVAS A IMPLEMENTAR COM VISTA À SUA MELHORIA E UMA FORMA OBJECTIVA DE CERTIFICAÇÃO. A REALIZAÇÃO DE AVALIAÇÕES PERIÓDICAS PERMITE MONITORIZAR A EVOLUÇÃO DA ORGANIZAÇÃO NA FORMA COMO GERE A INFORMAÇÃO E ESTABELECER OS PASSOS A SEGUIR NO SENTIDO DO SEU DESENVOLVIMENTO ESTRATÉGICO NO QUE RESPEITA À GESTÃO DE INFORMAÇÃO.